Title:
BIOLOGICAL AGENT CRYSTAL, AND POLYMER GEL, AND SUSTAINED RELEASE FORMULATION FOR CONTAINING PARTICLE SUSPENSION
Document Type and Number:
Japanese Patent JP2013079288
Kind Code:
A
Abstract:
To provide a sustained release formulation that contains a crystal of biological agent, polymer gel, and particle suspension.
This invention is directed to the sustained release formulations of a biological agent that enables sustained bioavailability. A bone morphogenetic protein can be pointed out as a desirable biological agent. The diseases expected to be improved and/treated by this formulation include a skeletal tissue disease (for instance, degenerative joint disease and other osteochondral disease, if not limited thereto). This formulation is particularly suitable for the treatment of a tissue site where there is a minimal or no vaascular formation (for instance, intraarticular, interjoint, or meniscal site, if not limited thereto).
Inventors:
JAWOROWICZ WARREN
Application Number:
JP2013016463A
Publication Date:
May 02, 2013
Filing Date:
January 31, 2013
Export Citation:
Assignee:
STRYKER CORP
International Classes:
A61K38/00; A61K9/06; A61K9/10; A61K9/14; A61P1/02; A61P1/04; A61P1/16; A61P9/10; A61P13/12; A61P17/02; A61P19/02; A61P19/10; A61P21/00; A61P25/00; A61P25/02; A61P25/16; A61P27/02; C07K14/51; C07K14/495
Domestic Patent References:
| JP2005506951A | 2005-03-10 |
Foreign References:
| WO2005115438A1 | 2005-12-08 |
Other References:
JPN6013046162; 三木邦夫と原田繁春: '蒸気拡散法によるタンパク質の結晶化' 日本結晶学会誌 Ｖｏｌ．３１ Ｎｏ．２５６, 1989, ｐｐ．３１．５-１０ - ３１．５-１４
JPN5010000559; ＪＥＮ Ａ ｅｔ ａｌ．: ＪＯＵＲＮＡＬ ＯＦ ＣＯＮＴＲＯＬＬＥＤ ＲＥＬＥＡＳＥ Ｖｏｌ．７８ Ｎｏ．１-３, 20020117, ｐｐ．２５-３４, ＥＬＳＥＶＩＥＲ
JPN5010000560; ＬＵＧＩＮＢＵＥＨＬ Ｖ ｅｔ ａｌ．: ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＳ ＡＮＤ ＢＩＯＰＨＡＲＭＡＣＥＵＴＩＣＳ Ｖｏｌ．５８ Ｎｏ．２, 20040901, ｐｐ．１９７-２０８, ＥＬＳＥＶＩＥＲ ＳＣＩＥＮＣＥ ＰＵＢＬＩＳＨＥＲＳ Ｂ．Ｖ．
JPN5010000564; ＢＡＳＵ ＳＫ ｅｔ ａｌ．: ＥＸＰＥＲＴ ＯＰＩＮＩＯＮ ＯＮ ＢＩＯＬＯＧＩＣＡＬ ＴＨＥＲＡＰＹ Ｖｏｌ．４ Ｎｏ．３, 20040301, ｐｐ．３０１-３１７, ＡＳＨＬＥＹ
JPN5010000561; Ｂｅａｌｓ ＪＭ ａｎｄ Ｓｈａｎａｆｅｌｔ ＡＢ: ＤＲＵＧ ＤＩＳＣＯＶＥＲＹ ＴＯＤＡＹ：ＴＥＣＨＮＯＬＯＧＩＥＳ Ｖｏｌ．３ Ｎｏ．１, 20060401, ｐｐ．８７-９４, ＥＬＳＥＶＩＥＲ
JPN5010000565; ＰＥＣＨＥＮＯＶ Ｓ ｅｔ ａｌ．: ＪＯＵＲＮＡＬ ＯＦ ＣＯＮＴＲＯＬＬＥＤ ＲＥＬＥＡＳＥ Ｖｏｌ．９６ Ｎｏ．１, 20040416, ｐｐ．１４９-１５８, ＥＬＳＥＶＩＥＲ
JPN5010000559; ＪＥＮ Ａ ｅｔ ａｌ．: ＪＯＵＲＮＡＬ ＯＦ ＣＯＮＴＲＯＬＬＥＤ ＲＥＬＥＡＳＥ Ｖｏｌ．７８ Ｎｏ．１-３, 20020117, ｐｐ．２５-３４, ＥＬＳＥＶＩＥＲ
JPN5010000560; ＬＵＧＩＮＢＵＥＨＬ Ｖ ｅｔ ａｌ．: ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＳ ＡＮＤ ＢＩＯＰＨＡＲＭＡＣＥＵＴＩＣＳ Ｖｏｌ．５８ Ｎｏ．２, 20040901, ｐｐ．１９７-２０８, ＥＬＳＥＶＩＥＲ ＳＣＩＥＮＣＥ ＰＵＢＬＩＳＨＥＲＳ Ｂ．Ｖ．
JPN5010000564; ＢＡＳＵ ＳＫ ｅｔ ａｌ．: ＥＸＰＥＲＴ ＯＰＩＮＩＯＮ ＯＮ ＢＩＯＬＯＧＩＣＡＬ ＴＨＥＲＡＰＹ Ｖｏｌ．４ Ｎｏ．３, 20040301, ｐｐ．３０１-３１７, ＡＳＨＬＥＹ
JPN5010000561; Ｂｅａｌｓ ＪＭ ａｎｄ Ｓｈａｎａｆｅｌｔ ＡＢ: ＤＲＵＧ ＤＩＳＣＯＶＥＲＹ ＴＯＤＡＹ：ＴＥＣＨＮＯＬＯＧＩＥＳ Ｖｏｌ．３ Ｎｏ．１, 20060401, ｐｐ．８７-９４, ＥＬＳＥＶＩＥＲ
JPN5010000565; ＰＥＣＨＥＮＯＶ Ｓ ｅｔ ａｌ．: ＪＯＵＲＮＡＬ ＯＦ ＣＯＮＴＲＯＬＬＥＤ ＲＥＬＥＡＳＥ Ｖｏｌ．９６ Ｎｏ．１, 20040416, ｐｐ．１４９-１５８, ＥＬＳＥＶＩＥＲ
Attorney, Agent or Firm:
Takeshi Oshio